{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:05:25Z","timestamp":1784286325094,"version":"3.55.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s41669-026-00640-3","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:44:28Z","timestamp":1772469868000},"page":"661-677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Older Adults in Portugal"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6940-6367","authenticated-orcid":false,"given":"Eleftherios","family":"Zarkadoulas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7807-6798","authenticated-orcid":false,"given":"F\u00e1bio","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5736-6519","authenticated-orcid":false,"given":"Joana","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8442-0106","authenticated-orcid":false,"given":"Francisco","family":"Madeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6306-3653","authenticated-orcid":false,"given":"Maarten J","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"4","key":"640_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/2051013615599151","volume":"3","author":"RW Johnson","year":"2015","unstructured":"Johnson RW, Alvarez-Pasquin MJ, Bijl M, Franco E, Gaillat J, Clara JG, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015;3(4):109\u201320. https:\/\/doi.org\/10.1177\/2051013615599151.","journal-title":"Ther Adv Vaccines"},{"key":"640_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.16","volume":"1","author":"AA Gershon","year":"2015","unstructured":"Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015;1:15016. https:\/\/doi.org\/10.1038\/nrdp.2015.16.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"640_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJMcp1302674","volume":"369","author":"JI Cohen","year":"2013","unstructured":"Cohen JI. Herpes zoster. N Engl J Med. 2013;369(3):255\u201363. https:\/\/doi.org\/10.1056\/NEJMcp1302674.","journal-title":"N Engl J Med"},{"issue":"6","key":"640_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. https:\/\/doi.org\/10.1136\/bmjopen-2014-004833.","journal-title":"BMJ Open"},{"issue":"7","key":"640_CR5","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s40121-024-01002-4","volume":"13","author":"N Giannelos","year":"2024","unstructured":"Giannelos N, Curran D, Nguyen C, Kagia C, Vroom N, Vroling H. The incidence of herpes zoster complications: a systematic literature review. Infect Dis Ther. 2024;13(7):1461\u201386. https:\/\/doi.org\/10.1007\/s40121-024-01002-4.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"640_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/j.pain.0000000000000307","volume":"157","author":"HJ Forbes","year":"2016","unstructured":"Forbes HJ, Thomas SL, Smeeth L, Clayton T, Farmer R, Bhaskaran K, et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain. 2016;157(1):30\u201354. https:\/\/doi.org\/10.1097\/j.pain.0000000000000307.","journal-title":"Pain"},{"issue":"2","key":"640_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4065\/mcp.2010.0618","volume":"86","author":"BP Yawn","year":"2011","unstructured":"Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc. 2011;86(2):88\u201393. https:\/\/doi.org\/10.4065\/mcp.2010.0618.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"640_CR8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s13555-024-01101-7","volume":"14","author":"R Parikh","year":"2024","unstructured":"Parikh R, Spence O, Giannelos N, Kaan I. Herpes zoster recurrence: a narrative review of the literature. Dermatol Ther (Heidelb). 2024;14(3):569\u201392. https:\/\/doi.org\/10.1007\/s13555-024-01101-7.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"640_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-017-0420-9","volume":"17","author":"L Varghese","year":"2017","unstructured":"Varghese L, Standaert B, Olivieri A, Curran D. The temporal impact of aging on the burden of herpes zoster. BMC Geriatr. 2017;17(1):30. https:\/\/doi.org\/10.1186\/s12877-017-0420-9.","journal-title":"BMC Geriatr"},{"issue":"12","key":"640_CR10","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1016\/j.mayocp.2017.10.009","volume":"92","author":"K Kawai","year":"2017","unstructured":"Kawai K, Yawn BP. Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc. 2017;92(12):1806\u201321. https:\/\/doi.org\/10.1016\/j.mayocp.2017.10.009.","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"640_CR11","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1093\/cid\/ciz1090","volume":"71","author":"SL McKay","year":"2020","unstructured":"McKay SL, Guo A, Pergam SA, Dooling K. Herpes zoster risk in immunocompromised adults in the United States: a systematic review. Clin Infect Dis. 2020;71(7):e125\u201334. https:\/\/doi.org\/10.1093\/cid\/ciz1090.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"640_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa005","volume":"7","author":"F Marra","year":"2020","unstructured":"Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020;7(1):ofaa005. https:\/\/doi.org\/10.1093\/ofid\/ofaa005.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"640_CR13","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s15010-023-02156-y","volume":"52","author":"M Steinmann","year":"2024","unstructured":"Steinmann M, Lampe D, Grosser J, Schmidt J, Hohoff ML, Fischer A, et al. Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and heterogeneity patterns. Infection. 2024;52(3):1009\u201326. https:\/\/doi.org\/10.1007\/s15010-023-02156-y.","journal-title":"Infection"},{"issue":"1","key":"640_CR14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40121-021-00567-8","volume":"11","author":"D Curran","year":"2022","unstructured":"Curran D, Callegaro A, Fahrbach K, Neupane B, Vroling H, van Oorschot D, et al. Meta-regression of herpes zoster incidence worldwide. Infect Dis Ther. 2022;11(1):389\u2013403. https:\/\/doi.org\/10.1007\/s40121-021-00567-8.","journal-title":"Infect Dis Ther"},{"key":"640_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-015-1514-y","volume":"15","author":"A Gater","year":"2015","unstructured":"Gater A, Uhart M, McCool R, Preaud E. The humanistic, economic and societal burden of herpes zoster in Europe: a critical review. BMC Public Health. 2015;15:193. https:\/\/doi.org\/10.1186\/s12889-015-1514-y.","journal-title":"BMC Public Health"},{"issue":"2","key":"640_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/j.pain.0000000000001718","volume":"161","author":"M Harvey","year":"2020","unstructured":"Harvey M, Prosser LA, Rose AM, Ortega-Sanchez IR, Harpaz R. Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition. Pain. 2020;161(2):361\u20138. https:\/\/doi.org\/10.1097\/j.pain.0000000000001718.","journal-title":"Pain"},{"key":"640_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-8-37","volume":"8","author":"RW Johnson","year":"2010","unstructured":"Johnson RW, Bouhassira D, Kassianos G, Leplege A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8:37. https:\/\/doi.org\/10.1186\/1741-7015-8-37.","journal-title":"BMC Med"},{"issue":"8","key":"640_CR18","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/AJP.0000000000001129","volume":"39","author":"S Matthews","year":"2023","unstructured":"Matthews S, Curran D, Sabater Cabrera E, Boutry C, Lecrenier N, Cunningham AL, et al. An analysis of how herpes zoster pain affects health-related quality of life of placebo patients from 3 randomized phase III studies. Clin J Pain. 2023;39(8):386\u201393. https:\/\/doi.org\/10.1097\/AJP.0000000000001129.","journal-title":"Clin J Pain"},{"key":"640_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/25151355221084535","volume":"10","author":"CX Pan","year":"2022","unstructured":"Pan CX, Lee MS, Nambudiri VE. Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review. Ther Adv Vaccines Immunother. 2022;10:25151355221084535. https:\/\/doi.org\/10.1177\/25151355221084535.","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"1","key":"640_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s40267-024-01126-0","volume":"41","author":"S Duque","year":"2025","unstructured":"Duque S, Marinho A, Almeida P, Marques Pereira R, Buzaco R. Expanding the coverage of herpes zoster vaccination recommendations in European countries: the example of Portugal. Drugs Ther Perspect. 2025;41(1):34\u201343. https:\/\/doi.org\/10.1007\/s40267-024-01126-0.","journal-title":"Drugs Ther Perspect"},{"key":"640_CR21","unstructured":"European Medicines Agency (EMA). Zostavax. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zostavax. Accessed 20 Aug 2025."},{"key":"640_CR22","unstructured":"European Medicines Agency (EMA). Shingrix. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/shingrix. Accessed 7 July 2024."},{"issue":"3","key":"640_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2278362","volume":"19","author":"A Mwakingwe-Omari","year":"2023","unstructured":"Mwakingwe-Omari A, Lecrenier N, Naficy A, Curran D, Posiuniene I. Recombinant zoster vaccine in immunocompetent and immunocompromised adults: a review of clinical studies. Hum Vaccin Immunother. 2023;19(3):2278362. https:\/\/doi.org\/10.1080\/21645515.2023.2278362.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"640_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2445384","volume":"21","author":"AL Cunningham","year":"2025","unstructured":"Cunningham AL, Sandgren KJ, Taylor J. Current status of immunisation for herpes zoster. Hum Vaccin Immunother. 2025;21(1):2445384. https:\/\/doi.org\/10.1080\/21645515.2024.2445384.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"640_CR25","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/14760584.2024.2382725","volume":"23","author":"F Roman","year":"2024","unstructured":"Roman F, Burny W, Ceregido MA, Laupeze B, Temmerman ST, Warter L, et al. Adjuvant system AS01: from mode of action to effective vaccines. Expert Rev Vaccines. 2024;23(1):715\u201329. https:\/\/doi.org\/10.1080\/14760584.2024.2382725.","journal-title":"Expert Rev Vaccines"},{"issue":"22","key":"640_CR26","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1501184.","journal-title":"N Engl J Med"},{"issue":"11","key":"640_CR27","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1603800.","journal-title":"N Engl J Med"},{"key":"640_CR28","doi-asserted-by":"publisher","first-page":"103241","DOI":"10.1016\/j.eclinm.2025.103241","volume":"83","author":"A Strezova","year":"2025","unstructured":"Strezova A, D\u00edez Domingo JC, Anthony L, Eto T, Andrews C, Arns C, et al. Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications. eClinicalMedicine. 2025;83:103241. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103241.","journal-title":"eClinicalMedicine."},{"issue":"9","key":"640_CR29","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/14760584.2021.1956906","volume":"20","author":"R Parikh","year":"2021","unstructured":"Parikh R, Widenmaier R, Lecrenier N. A practitioner\u2019s guide to the recombinant zoster vaccine: review of national vaccination recommendations. Expert Rev Vaccines. 2021;20(9):1065\u201375. https:\/\/doi.org\/10.1080\/14760584.2021.1956906.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"640_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.vaccine.2022.10.063","volume":"41","author":"KM Sullivan","year":"2023","unstructured":"Sullivan KM, Farraye FA, Winthrop KL, Willer DO, Vink P, Tavares-Da-Silva F. Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions. Vaccine. 2023;41(1):36\u201348. https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.063.","journal-title":"Vaccine"},{"issue":"3","key":"640_CR31","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s00103-019-02882-5","volume":"62","author":"A Siedler","year":"2019","unstructured":"Siedler A, Koch J, Garbe E, Hengel H, von Kries R, Ledig T, et al. Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine: statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019;62(3):352\u201376. https:\/\/doi.org\/10.1007\/s00103-019-02882-5.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"1","key":"640_CR32","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2366353","volume":"20","author":"A Garcia","year":"2024","unstructured":"Garcia A, Vallejo-Aparicio LA, Cambronero Martinez R. The public health impact of recombinant herpes zoster vaccination in adults over 50 years in Spain. Hum Vaccin Immunother. 2024;20(1):2366353. https:\/\/doi.org\/10.1080\/21645515.2024.2366353.","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"640_CR33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.24950\/rspmi.1886","volume":"30","author":"S Duque","year":"2023","unstructured":"Duque S, Marinho A, Almeida P, Pereira RM, Buzaco R. Recomenda\u00e7\u00f5es para a Vacina\u00e7\u00e3o contra o Herpes Zoster: Documento de Consenso da Sociedade Portuguesa de Medicina Interna e da Associa\u00e7\u00e3o Portuguesa de Medicina Geral e Familiar. Med Interna. 2023;30(3):180\u201391. https:\/\/doi.org\/10.24950\/rspmi.1886.","journal-title":"Med Interna"},{"key":"640_CR34","doi-asserted-by":"publisher","DOI":"10.1159\/000541873","author":"P Melo","year":"2024","unstructured":"Melo P, Freitas P, Carvalho R, Sim\u00f5es Carvalho F, Jord\u00e3o S, do Vale S, et al. Vaccination in adults with diabetes mellitus: a position statement of the Diabetes Mellitus Study Group of the Portuguese Society of Endocrinology, Diabetes, and Metabolism. Endocrinol Insights. 2024. https:\/\/doi.org\/10.1159\/000541873.","journal-title":"Endocrinol Insights"},{"issue":"10","key":"640_CR35","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1080\/21645515.2017.1345399","volume":"13","author":"D Curran","year":"2017","unstructured":"Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, Colindres R, et al. Assessment of the potential public health impact of herpes zoster vaccination in Germany. Hum Vaccin Immunother. 2017;13(10):2213\u201321. https:\/\/doi.org\/10.1080\/21645515.2017.1345399.","journal-title":"Hum Vaccin Immunother"},{"issue":"33","key":"640_CR36","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1016\/j.vaccine.2018.07.005","volume":"36","author":"D Curran","year":"2018","unstructured":"Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018;36(33):5037\u201345. https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.005.","journal-title":"Vaccine"},{"issue":"2","key":"640_CR37","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s13555-018-0236-3","volume":"8","author":"D Watanabe","year":"2018","unstructured":"Watanabe D, Mizukami A, Holl K, Curran D, Van Oorschot D, Varghese L, et al. The potential public health impact of Herpes Zoster vaccination of people aged \u2265 50 years in Japan: results of a Markov model analysis. Dermatol Ther (Heidelb). 2018;8(2):269\u201384. https:\/\/doi.org\/10.1007\/s13555-018-0236-3.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"640_CR38","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s40258-019-00491-6","volume":"17","author":"A McGirr","year":"2019","unstructured":"McGirr A, Van Oorschot D, Widenmaier R, Stokes M, Ganz ML, Jung H, et al. Public health impact and cost-effectiveness of non-live adjuvanted recombinant zoster vaccine in Canadian adults. Appl Health Econ Health Policy. 2019;17(5):723\u201332. https:\/\/doi.org\/10.1007\/s40258-019-00491-6.","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"640_CR39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/21645515.2018.1509645","volume":"15","author":"D Van Oorschot","year":"2019","unstructured":"Van Oorschot D, Anastassopoulou A, Poulsen Nautrup B, Varghese L, von Krempelhuber A, Neine M, et al. Cost-effectiveness of the recombinant zoster vaccine in the German population aged \u226560 years old. Hum Vaccin Immunother. 2019;15(1):34\u201344. https:\/\/doi.org\/10.1080\/21645515.2018.1509645.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"640_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025553","volume":"9","author":"DAM van Oorschot","year":"2019","unstructured":"van Oorschot DAM, Hunjan M, Bracke B, Lorenc S, Curran D, Starkie-Camejo H. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme. BMJ Open. 2019;9(5):e025553. https:\/\/doi.org\/10.1136\/bmjopen-2018-025553.","journal-title":"BMJ Open"},{"issue":"2","key":"640_CR41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/21645515.2019.1657753","volume":"16","author":"A Volpi","year":"2020","unstructured":"Volpi A, Boccalini S, Dari S, Clarke C, Curran D, Loiacono I, et al. The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy. Hum Vaccin Immunother. 2020;16(2):327\u201334. https:\/\/doi.org\/10.1080\/21645515.2019.1657753.","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"640_CR42","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1080\/21645515.2021.2002085","volume":"17","author":"D Curran","year":"2021","unstructured":"Curran D, Van Oorschot D, Matthews S, Hain J, Salem AE, Schwarz M. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany. Hum Vaccin Immunother. 2021;17(12):5296\u2013303. https:\/\/doi.org\/10.1080\/21645515.2021.2002085.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"640_CR43","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s13555-022-00744-8","volume":"12","author":"L Teng","year":"2022","unstructured":"Teng L, Mizukami A, Ng C, Giannelos N, Curran D, Sato T, et al. Cost-effectiveness analysis update of the adjuvanted recombinant zoster vaccine in Japanese older adults. Dermatol Ther (Heidelb). 2022;12(6):1447\u201367. https:\/\/doi.org\/10.1007\/s13555-022-00744-8.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"640_CR44","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2176065","volume":"19","author":"PKS Chan","year":"2023","unstructured":"Chan PKS, Wong MCS, Chan M, Ching K, Giannelos N, Ng C. Public health impact of herpes zoster vaccination on older adults in Hong Kong. Hum Vaccin Immunother. 2023;19(1):2176065. https:\/\/doi.org\/10.1080\/21645515.2023.2176065.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"640_CR45","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2348839","volume":"20","author":"H Oh","year":"2024","unstructured":"Oh H, Tan C, Williams C, Giannelos N, Ng C. Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study. Hum Vaccin Immunother. 2024;20(1):2348839. https:\/\/doi.org\/10.1080\/21645515.2024.2348839.","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"640_CR46","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s41669-024-00483-w","volume":"8","author":"S George","year":"2024","unstructured":"George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, et al. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. PharmacoEcon Open. 2024;8(3):481\u201392. https:\/\/doi.org\/10.1007\/s41669-024-00483-w.","journal-title":"PharmacoEcon Open"},{"issue":"1","key":"640_CR47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40121-024-01073-3","volume":"14","author":"M Hunjan","year":"2025","unstructured":"Hunjan M, Curran D, Marijam A, Vekria Y, Giannelos N. Modelled public health impact of introducing adjuvanted recombinant zoster vaccine into the UK national immunisation programme. Infect Dis Ther. 2025;14(1):105\u201319. https:\/\/doi.org\/10.1007\/s40121-024-01073-3.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"640_CR48","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2168952","volume":"19","author":"N Giannelos","year":"2023","unstructured":"Giannelos N, Ng C, Curran D. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: an updated critical review. Hum Vaccin Immunother. 2023;19(1):2168952. https:\/\/doi.org\/10.1080\/21645515.2023.2168952.","journal-title":"Hum Vaccin Immunother"},{"issue":"34","key":"640_CR49","doi-asserted-by":"publisher","first-page":"E932","DOI":"10.1503\/cmaj.190274","volume":"191","author":"M Drolet","year":"2019","unstructured":"Drolet M, Zhou Z, Sauvageau C, DeWals P, Gilca V, Amini R, et al. Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study. CMAJ. 2019;191(34):E932\u20139. https:\/\/doi.org\/10.1503\/cmaj.190274.","journal-title":"CMAJ"},{"issue":"6","key":"640_CR50","doi-asserted-by":"publisher","first-page":"380","DOI":"10.7326\/M18-2347","volume":"170","author":"LA Prosser","year":"2019","unstructured":"Prosser LA, Harpaz R, Rose AM, Gebremariam A, Guo A, Ortega-Sanchez IR, et al. A cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: input for national recommendations. Ann Intern Med. 2019;170(6):380\u20138. https:\/\/doi.org\/10.7326\/M18-2347.","journal-title":"Ann Intern Med"},{"issue":"1","key":"640_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.11.1351.","journal-title":"Value Health"},{"key":"640_CR52","unstructured":"Instituto Nacional de Estat\u00edstica. Popula\u00e7\u00e3o residente (S\u00e9rie longa, in\u00edcio 1991\u2014N.o) por Local de resid\u00eancia (NUTS\u20142013), Sexo e Idade; Anual. Lisboa, Portugal: Instituto Nacional de Estat\u00edstica; 2024. https:\/\/www.ine.pt\/xportal\/xmain?xpid=INE&xpgid=ine_indicadores&indOcorrCod=0008273&xlang=pt. Accessed 7 July 2024."},{"key":"640_CR53","unstructured":"Instituto Nacional de Estat\u00edstica. Portuguese life tables 2019\u20132021; Lisboa, Portugal: Instituto Nacional de Estat\u00edstica; 2024. https:\/\/www.ine.pt\/xportal\/xmain?xpid=INE&xpgid=ine_indicadores&indOcorrCod=0004160&&contexto=bd&selTab=tab2. Accessed 7 July 2024."},{"issue":"6","key":"640_CR54","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s40121-025-01161-y","volume":"14","author":"N Giannelos","year":"2025","unstructured":"Giannelos N, Curran C, Matthews S, Carrico J, Cunningham AL. The potential impact of increased recombinant zoster vaccine uptake in older adults worldwide. Infect Dis Ther. 2025;14(6):1327\u201341. https:\/\/doi.org\/10.1007\/s40121-025-01161-y.","journal-title":"Infect Dis Ther"},{"key":"640_CR55","unstructured":"Silva F, Castanheira RC, Zarkadoulas E, Figueira D, Bulhosa C, Borges M, et al. Landscape of Herpes Zoster Infections in Portugal. In: The 1st annual meeting of the Portuguese Association of General and Family Medicine (APMGF); November 21\u201323, 2024, F\u00e1tima, Portugal."},{"issue":"2","key":"640_CR56","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jinf.2014.08.018","volume":"70","author":"K Hillebrand","year":"2015","unstructured":"Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E. Incidence of herpes zoster and its complications in Germany, 2005-2009. J Infect. 2015;70(2):178\u201386. https:\/\/doi.org\/10.1016\/j.jinf.2014.08.018.","journal-title":"J Infect"},{"key":"640_CR57","unstructured":"Horn J, Damm O, Kretzschmar ME, Karch A, Siedler A, Ultsch B, et al. Mathematische Modellierung der Effekte des Varizellen-Impfprogramms in Deutschland: Abschlussbericht, Version 1.2. Braunschweig, Bielefeld, Utrecht, Berlin; 16.09.2014."},{"key":"640_CR58","unstructured":"Instituto Nacional de Estad\u00edstica. Estad\u00edsticas de defunciones seg\u00fan la causa de muerte. Resultados detallados. A\u00f1o 2020. Causa b\u00e1sica de defunci\u00f3n. Resultados nacionales. Madrid, Spain: Instituto Nacional de Estad\u00edstica; 2020. https:\/\/www.ine.es\/jaxi\/Tabla.htm?tpx=49913&L=0. Accessed 7 July 2024."},{"key":"640_CR59","unstructured":"Minist\u00e9rio da Sa\u00fade. Dire\u00e7\u00e3o-Geral da Sa\u00fade. Relat\u00f3rio Semanal de Vacina\u00e7\u00e3o Sazonal | 19\/03\/2024 | Vacina\u00e7\u00e3o sazonal contra a COVID-19 e contra a gripe. Lisboa, Portugal: Dire\u00e7\u00e3o-Geral da Sa\u00fade; 2024. https:\/\/covid19.min-saude.pt\/wp-content\/uploads\/2024\/03\/Relatorio_Vac_Sazonal_20240318.pdf. Accessed 7 July 2024."},{"issue":"6","key":"640_CR60","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.vaccine.2020.12.076","volume":"39","author":"B Ackerson","year":"2021","unstructured":"Ackerson B, Qian L, Sy LS, Bruxvoort K, Wu J, Luo Y, et al. Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older. Vaccine. 2021;39(6):926\u201332. https:\/\/doi.org\/10.1016\/j.vaccine.2020.12.076.","journal-title":"Vaccine"},{"key":"640_CR61","unstructured":"GSK Clinical study report ZOE-50. A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety, and immunogenicity of Shingrix in adults aged 50 years and older. GSK; 2016. GSK Study ID:110390"},{"key":"640_CR62","unstructured":"GSK. Clinical study report ZOE-70. A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety and immunogenicity of Shingrix in adults aged 70 years and older. GSK; 2016. GSK Study ID:113077"},{"issue":"18","key":"640_CR63","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1016\/j.vaccine.2019.03.043","volume":"37","author":"M Lopez-Fauqued","year":"2019","unstructured":"Lopez-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze FJ, et al. Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials. Vaccine. 2019;37(18):2482\u201393. https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.043.","journal-title":"Vaccine"},{"issue":"5","key":"640_CR64","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/aje\/kwac030","volume":"191","author":"WK Yih","year":"2022","unstructured":"Yih WK, Kulldorff M, Dashevsky I, Maro JC. A broad safety assessment of the recombinant herpes zoster vaccine. Am J Epidemiol. 2022;191(5):957\u201364. https:\/\/doi.org\/10.1093\/aje\/kwac030.","journal-title":"Am J Epidemiol"},{"key":"640_CR65","unstructured":"Di\u00e1rio da Rep\u00fablica. Portaria n.\u00ba 207\/2017. Di\u00e1rio da Rep\u00fablica N.\u00ba 132\/2017, de 11 julho, 2017. https:\/\/diariodarepublica.pt\/dr\/detalhe\/portaria\/207-2017-107669157. Accessed 7 July 2024."},{"key":"640_CR66","unstructured":"Di\u00e1rio da Rep\u00fablica. Portaria n.\u00ba 254\/2018. Di\u00e1rio da Rep\u00fablica N.\u00ba 173\/2018, de 7 setembro, 2018. https:\/\/diariodarepublica.pt\/dr\/detalhe\/portaria\/254-2018-116353279. Accessed 7 July 2024."},{"issue":"12","key":"640_CR67","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1016\/j.jval.2023.09.709","volume":"26","author":"F Silva","year":"2023","unstructured":"Silva F, Zarkadoulas E, Castanheira R, Castro O, Costa J, Silva Miguel L, et al. Ee443 burden of hospitalization related to adult herpes zoster infection in Portugal. Value Health. 2023;26(12):S136. https:\/\/doi.org\/10.1016\/j.jval.2023.09.709.","journal-title":"Value Health"},{"key":"640_CR68","unstructured":"Infarmed. Infomed - base de dados de medicamentos de uso humano. Detalhes do Medicamento: Shingrix. https:\/\/extranet.infarmed.pt\/INFOMED-fo\/index.xhtml. Accessed 7 July 2024."},{"issue":"6","key":"640_CR69","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s10198-012-0452-1","volume":"14","author":"B Ultsch","year":"2013","unstructured":"Ultsch B, Koster I, Reinhold T, Siedler A, Krause G, Icks A, et al. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ. 2013;14(6):1015\u201326. https:\/\/doi.org\/10.1007\/s10198-012-0452-1.","journal-title":"Eur J Health Econ"},{"key":"640_CR70","unstructured":"Instituto Nacional de Estat\u00edstica. Estat\u00edsticas do Emprego - Remunera\u00e7\u00e3o bruta mensal m\u00e9dia por trabalhador, dezembro de 2023. Lisboa, Portugal: Instituto Nacional de Estat\u00edstica; 2024."},{"key":"640_CR71","unstructured":"Instituto Nacional de Estat\u00edstica. Taxa de emprego (S\u00e9rie 2021 - %) por Local de resid\u00eancia (NUTS - 2013), Sexo, Grupo et\u00e1rio e N\u00edvel de escolaridade mais elevado completo; Anual. Lisboa, Portugal: Instituto Nacional de Estat\u00edstica; 2024. https:\/\/www.ine.pt\/xportal\/xmain?xpid=INE&xpgid=ine_indicadores&indOcorrCod=0006404&xlang=pt&contexto=bd&selTab=tab2. Accessed 7 July 2024."},{"issue":"9","key":"640_CR72","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s10198-022-01552-9","volume":"24","author":"PL Ferreira","year":"2023","unstructured":"Ferreira PL, Pereira LN, Antunes P, Ferreira LN. EQ-5D-5L Portuguese population norms. Eur J Health Econ. 2023;24(9):1411\u201320. https:\/\/doi.org\/10.1007\/s10198-022-01552-9.","journal-title":"Eur J Health Econ"},{"issue":"9","key":"640_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.2330","volume":"20","author":"D Curran","year":"2017","unstructured":"Curran D, Neine M, Starkie Camejo H, Hunjan M. Quality-adjusted life year (QALY) losses associated with herpes zoster and postherpetic neuralgia in immunocompromised (IC) and IC-free individuals aged \u2265 50 years of age in the UK population. Value Health. 2017;20(9):PA792. https:\/\/doi.org\/10.1016\/j.jval.2017.08.2330.","journal-title":"Value Health"},{"issue":"5","key":"640_CR74","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40261-024-01355-1","volume":"44","author":"N Giannelos","year":"2024","unstructured":"Giannelos N, Francq B, Curran D. Differential utility losses in herpes zoster cases between vaccinated and unvaccinated subjects: a meta-analysis of three clinical trials. Clin Drug Investig. 2024;44(5):293\u2013301. https:\/\/doi.org\/10.1007\/s40261-024-01355-1.","journal-title":"Clin Drug Investig"},{"issue":"7","key":"640_CR75","doi-asserted-by":"publisher","first-page":"489","DOI":"10.7326\/M15-0093","volume":"163","author":"P Le","year":"2015","unstructured":"Le P, Rothberg MB. Cost-effectiveness of herpes zoster vaccine for persons aged 50 years. Ann Intern Med. 2015;163(7):489\u201397. https:\/\/doi.org\/10.7326\/M15-0093.","journal-title":"Ann Intern Med"},{"key":"640_CR76","unstructured":"Perelman J, Soares M, Mateus C, Duarte A, Faria R, Ferreira L, et al. Orienta\u00e7\u00f5es metodol\u00f3gicas para estudos de avalia\u00e7\u00e3o econ\u00f3mica. Lisboa: Infarmed - Autoridade Nacional do Medicamento e Produtos de Sa\u00fade; 2019. https:\/\/www.infarmed.pt\/documents\/15786\/1431404\/Orienta%C3%A7%C3%B5es+Metodol%C3%B3gicas+para+Estudos+de+Avalia%C3%A7%C3%A3o+Econ%C3%B3mica+de+Medicamentos\/78d35a18-92a6-8fc4-5fde-24dab1968669. Accessed 7 July 2024."},{"issue":"8","key":"640_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081285","volume":"10","author":"D Tavares","year":"2022","unstructured":"Tavares D, Mourino H, Rodriguez CA, Saborido CM. Cost effectiveness of quadrivalent versus trivalent inactivated influenza vaccines for the Portuguese elderly population. Vaccines. 2022;10(8):1285. https:\/\/doi.org\/10.3390\/vaccines10081285.","journal-title":"Vaccines"},{"key":"640_CR78","unstructured":"European Union. EU country profile: Portugal. https:\/\/european-union.europa.eu\/principles-countries-history\/eu-countries\/portugal_en. Accessed 7 Feb 2025"},{"key":"640_CR79","unstructured":"GSK. Landscape of Varicella Zoster Virus (Herpes Zoster) infections in Portugal \u2013 Estimates of the number of people in treatment for HZ in Portugal. GSK Study ID: 219367. September 2024."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00640-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-026-00640-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00640-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T10:25:23Z","timestamp":1784283923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-026-00640-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["640"],"URL":"https:\/\/doi.org\/10.1007\/s41669-026-00640-3","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The copyright holder has been corrected from \u00a9 GlaxoSmithKline Biologicals SA 2026 to \u00a9 GSK Plc 2026.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Eleftherios Zarkadoulas and F\u00e1bio Silva are employed by and hold financial equities in GSK. Joana Alves and Francisco Madeira are employed by NOVA National School of Public Health, which received financial support from GSK to perform the work disclosed in this publication. Francisco Madeira received a research grant from ENSP NOVA, funded by GSK. MJ Postma holds stock or stock options in PAG BV (100%) and Health-Ecore (25%). All authors declare no other financial and non-financial relationships and activities.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EZ was involved in the design of the study. JA and FM collected and generated the data. EZ, FS, FM, and JA analyzed the data. EZ and MP interpreted the data. All authors participated in the development of this manuscript. FS led the publication development. All authors had full access to the data and gave their final approval and agree to be accountable for all aspects of the work.","order":2,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author upon reasonable request.","order":3,"name":"Ethics","label":"Data availability statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Microsoft Excel-based model used in this study is proprietary to GSK and cannot be shared.","order":7,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shingrix is a trademark owned by or licensed to the GSK group of companies. AS01 is a trademark owned by or licensed to the GSK group of companies.","order":8,"name":"Ethics","label":"Trademark","group":{"name":"EthicsHeading","label":"Declarations"}}]}}